ono 1078 has been researched along with Infarction, Middle Cerebral Artery in 8 studies
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls." | 5.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| "Oral montelukast (0." | 1.37 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. ( Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R, 2011) |
| "Montelukast was injected intraperitoneally either as multiple doses (once a day for 3 days and 30 min before MCAO) or as a single dose (at 30 min before, 30 min after, or 1 h after MCAO), respectively, and pranlukast and edaravone were used as controls." | 1.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| "Focal cerebral ischemia in mice was induced by permanent middle cerebral artery occlusion (MCAO)." | 1.33 | Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice. ( Chu, LS; Fang, SH; Wang, ML; Wei, EQ; Yu, GL; Zhang, WP; Zhou, Y, 2006) |
| "After middle cerebral artery occlusion (MCAO), the neurological deficits were evaluated 24 h later." | 1.32 | [An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia]. ( Wei, EQ; Xu, QQ; Yu, YP; Zheng, MZ; Zhu, CY; Zhu, YF, 2003) |
| "Focal cerebral ischemia was induced by permanent middle cerebral artery (MCA) occlusion in mice." | 1.31 | [Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice]. ( Wang, PL; Wang, RD; Wei, EQ; Zeng, LH; Zhang, WP, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, QJ | 1 |
| Wang, H | 1 |
| Liu, ZX | 1 |
| Fang, SH | 4 |
| Song, XM | 1 |
| Lu, YB | 1 |
| Zhang, WP | 6 |
| Sa, XY | 1 |
| Ying, HZ | 1 |
| Wei, EQ | 8 |
| Zhao, R | 1 |
| Shi, WZ | 1 |
| Zhang, YM | 1 |
| Mei, RH | 2 |
| Zhu, CY | 2 |
| Zhao, MH | 2 |
| Zeng, LH | 1 |
| Wang, RD | 1 |
| Wang, PL | 1 |
| Xu, QQ | 1 |
| Yu, YP | 1 |
| Zhu, YF | 1 |
| Zheng, MZ | 1 |
| Yu, GL | 3 |
| Zhang, SH | 1 |
| Xu, HM | 1 |
| Chu, LS | 3 |
| Zhang, Q | 1 |
| Chen, Z | 2 |
| Zhou, Y | 2 |
| Wang, ML | 2 |
8 other studies available for ono 1078 and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats.
Topics: Acute Disease; Animals; Brain; Brain Edema; Brain Ischemia; Chromones; Cyclohexanecarboxylic Acids; | 2015 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chroni | 2011 |
Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Chromones; Infarction, Middle Cerebral Artery; Leukotrien | 2002 |
[Protective effect of ONO-1078, a leukotriene antagonist, on focal cerebral ischemia in mice].
Topics: Animals; Brain; Brain Ischemia; Chromones; Dexamethasone; Infarction, Middle Cerebral Artery; Leukot | 2001 |
[An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia].
Topics: Animals; Behavior, Animal; Brain; Brain Ischemia; Chromones; Female; Hippocampus; Infarction, Middle | 2003 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; C | 2005 |
Pranlukast reduces neutrophil but not macrophage/microglial accumulation in brain after focal cerebral ischemia in mice.
Topics: Animals; Anti-Inflammatory Agents; Brain; Brain Ischemia; CD11b Antigen; Chromones; Immunoglobulin G | 2006 |
Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats.
Topics: Animals; Astrocytes; Brain Ischemia; Cerebral Infarction; Chromones; Disease Models, Animal; Encepha | 2006 |